| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
843.23(M) |
| Last
Volume: |
2,734,155 |
Avg
Vol: |
4,454,926 |
| 52
Week Range: |
$4.13 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aselage Steve |
Director |
• • – |
2020-08-31 |
4 |
A |
$4.15 |
$9,997 |
D/D |
2,409 |
28,613 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2020-08-31 |
4 |
A |
$4.15 |
$18,750 |
D/D |
4,518 |
69,605 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2020-08-31 |
4 |
A |
$4.15 |
$4,997 |
D/D |
1,204 |
63,315 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2020-08-31 |
4 |
A |
$4.15 |
$4,997 |
D/D |
1,204 |
12,408 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2020-08-11 |
4 |
B |
$4.08 |
$220,320 |
D/D |
54,000 |
54,000 |
2.74 |
92% |
|
| Ingram Robert Alexander |
Director |
• • – |
2020-06-01 |
4 |
A |
$4.50 |
$18,749 |
D/D |
4,171 |
65,087 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2020-06-01 |
4 |
A |
$4.50 |
$4,998 |
D/D |
1,112 |
11,204 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2020-06-01 |
4 |
A |
$4.50 |
$9,997 |
D/D |
2,224 |
62,111 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2020-06-01 |
4 |
A |
$4.50 |
$4,998 |
D/D |
1,112 |
26,204 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2020-03-01 |
4 |
A |
$3.00 |
$9,999 |
D/D |
3,333 |
59,887 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2020-03-01 |
4 |
A |
$3.00 |
$4,998 |
D/D |
1,666 |
10,092 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2020-03-01 |
4 |
A |
$3.00 |
$4,998 |
D/D |
1,666 |
25,092 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2020-03-01 |
4 |
A |
$3.00 |
$18,750 |
D/D |
6,250 |
60,916 |
|
- |
|
| Jones Michael L |
Exec Director, Finance - PAOOf |
• – – |
2020-01-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
848 |
|
48% |
|
| Hutson Nancy J |
Director |
• • – |
2019-12-01 |
4 |
A |
$2.85 |
$9,998 |
D/D |
3,508 |
56,554 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2019-12-01 |
4 |
A |
$2.85 |
$4,999 |
D/D |
1,754 |
23,426 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2019-12-01 |
4 |
A |
$2.85 |
$18,747 |
D/D |
6,578 |
54,666 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2019-12-01 |
4 |
A |
$2.85 |
$4,999 |
D/D |
1,754 |
8,426 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$7,250 |
D/D |
5,000 |
6,672 |
2.39 |
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$72,500 |
D/D |
50,000 |
778,086 |
2.81 |
- |
|
| Sniecinski Megan |
Chief Business Officer |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$65,250 |
D/D |
45,000 |
45,000 |
2.74 |
- |
|
| Aselage Steve |
Director |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$21,750 |
D/D |
15,000 |
21,672 |
2.39 |
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$29,000 |
D/D |
20,000 |
48,088 |
2.39 |
- |
|
| Lee Kenneth B Jr |
Director |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$7,250 |
D/D |
5,000 |
15,252 |
2.39 |
- |
|
| Babu Yarlagadda S |
Senior VP - Drug Discovery |
• • – |
2019-11-18 |
4 |
B |
$1.45 |
$36,250 |
D/D |
25,000 |
155,587 |
2.74 |
- |
|
77 Records found
|
|
Page 3 of 4 |
|
|
0.03 (0.67%) 
